8 arrested in Collierville for possession of firearms, drugs
MEMPHIS, Tenn. — Eight people were arrested in a Collierville neighborhood for possession of drugs and firearms on Saturday, according to Collierville Police.
On May 31, at 10 p.m., officers responded to a large gathering in a neighborhood near Mayfield Road.
Reports say the complainant called about vehicles blocking the road. When officers arrived, they noticed many vehicles and detected a strong odor coming from several cars.
Men seen carrying stolen counter, faucet on bikes after Midtown burglary
Police say additional calls were received from nearby residents reporting that vehicles were parked in their yards.
According to police, eight Memphians were arrested and cited for improper parking, and some were charged with multiple firearm charges, public intoxication, disorderly conduct, and possession of a controlled substance.
Two people were charged with felony narcotics charges and felony firearm charges.
Police seized 44 grams of marijuana, 347 Oxycodone tablets, 59 Xanax tablets, three Adderall tablets, and one handgun.
Police say the Town of Collierville Code Enforcement will be following up with additional town ordinance violations with the organizer and homeowner.
No injuries were reported.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
26 minutes ago
- Associated Press
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Annamycin delivering better performance 7thline than would be expected even in 2ndline for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and Progression Free Survival ('PFS') Clinical Benefit Rate ('CBR') was 59.4% (n=32), comprised of 18 subjects with stable disease and 1 subject with a partial response Potential to address 13,500 new incidents of STS each year and market opportunity expected to grow to $2.6B by 20301 On-demand video webcast with members of the Moleculin management team and internationally renowned Key Opinion Leaders available Thursday, June 5th HOUSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today reported positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases ('STS lung mets') (MB-107). The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1B determined the Maximum Tolerable Dose and Recommended Phase 2 Dose ('MTD', 'RP2D' respectively) and safety of Annamycin and in Phase 2 explored the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung mets for which chemotherapy was considered appropriate. For more information about the MB-107 trial visit and reference identifier NCT04887298. 'These positive topline results from MB-107 are incredibly encouraging. The impact Annamycin demonstrated on median overall survival, particularly with patients who received multiple prior chemotherapy regimens, exceeded expectations. Additionally, the improvement seen with PFS after two doses represents a real potential for Annamycin to provide a meaningful treatment option for the treatment of STS lung mets,' commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. 'Looking ahead, we believe these results strongly support further evaluations of Annamycin for the treatment of STS lung mets and we look forward to exploring opportunities to potentially bring this important treatment option to patients.' Topline Efficacy Results Summary Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for the treatment of soft tissue sarcoma. Furthermore, Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the EMA. On-Demand Webcast Details An on-demand Virtual STS Lung Mets KOL Webcast to discuss the MB-107 data will be available for investors, analysts, and other interested parties on Thursday, June 5, 2025 beginning at 8:30 AM ET. For the event, Walter Klemp, Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of Moleculin will be joined by Key Opinion Leaders: Mohamad Cherry, MD, Medical Director of Hematology at Atlantic Health System; Prof. Bernd Kasper, Sarcoma Unit of the Mannheim Cancer Center (MCC) at the Mannheim University Medical Center, University of Heidelberg; and Sant P. Chawla, MD, Director, Sarcoma Oncology Center, Director, Cancer Center of Southern California. Interested participants and investors may access the on-demand video webcast on the Events page of the Investors section of the Moleculin website, The webcast will be accessible for 90 days. About STS Lung Mets Soft tissue sarcoma is a type of cancer that originates in the soft tissues of the body, including muscles, tendons, fat, blood vessels and nerves. Lung metastases are a common occurrence in STS, and can impact overall survival. According to The American Cancer Society approximately 13,500 individuals, both adults and children, will be diagnosed with soft tissue sarcoma in 20252. Soft tissue sarcomas account for 1% of all adult cancers, 7% of cancers in children up to age 15, and 3% of cancers in children under the age of 14. The Soft Tissue Sarcoma Market was valued at USD 1.58 Billion in 2024, and is expected to reach USD 2.57 Billion by 2030, rising at a CAGR of 8.43%. OS for standard of care for metastatic STS has been estimated at 8-12 months and certain experimental targeted and cytotoxic therapies (as monotherapies or some in combination) have yielded OS of 13.4 months as second line therapy.3 MB-107 Study Design In Phase 2, Annamycin was administered as an intravenous (IV) infusion over 2 hours on Day 1, followed by 20 days off (1 cycle = 21 days). Subjects visit the study site every 21 days (±3 days) at which time safety monitoring – including for adverse events (AEs), as well as a physical examination, laboratory evaluations (clinical chemistry, complete blood count), vital signs, weight measurements, Eastern Cooperative Oncology Group (ECOG) performance status, and electrocardiograms (ECGs) – is performed, followed by an IV infusion of study drug. Cardiac function is followed by echocardiogram (ECHO) scans at screening, at the end of the first two cycles and then following every other cycle thereafter, at the End of Treatment visit, and if feasible, during follow up at 6 months (±1 month) and 1 year (±1 month) after study drug discontinuation. As long as the Investigator considers that the benefits of treatment with Annamycin continue to outweigh the risks, treatment will continue every 21 days until tumor progression is observed or unacceptable toxicity occurs. Tumor response is monitored every 6 weeks (±1 week) from Cycle 1 Day 1 during treatment, at the End of Treatment visit, and then every 3 months (±1 month) until disease progression using RECIST 1.1 criteria. Those subjects who leave the study after a maximum response is achieved and who do not start another therapy will be followed every 3 months (±1 month) for progression-free survival (PFS). If a subject receives further therapy after discontinuing from the study, they will be followed only for overall survival (OS) and if feasible, follow-up ECHO scans at 6 months (±1 month) and 1 year (±1 month) were conducted after study drug discontinuation. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the release of the initial data on the first 45 subjects in the trial and the Company's ability to reconcile the US and EU protocols with the FDA and EMA, respectively. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. 'Risk Factors' in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact: JTC Team, LLC Jenene Thomas (908) 824-0775 [email protected] 1 2 American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025. Available at 3 Comandone A, et al; 'Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials'; The Oncologist 2017;22:1518–1527
Associated Press
27 minutes ago
- Associated Press
Airgain Launches AirgainConnect® Go-Kit Pro: The Most Compact Mobile Rapid Response 5G Connectivity Kit for First Responders and Remote Operations
SAN DIEGO--(BUSINESS WIRE)--Jun 4, 2025-- Airgain, Inc. (NASDAQ: AIRG), a leading provider of advanced wireless connectivity solutions, today announced the availability of AirgainConnect ® Go-Kit Pro, the most compact Mobile Rapid Response 5G Connectivity Kit available today. Built for mission-critical field operations, Go-Kit Pro is rugged, fully integrated, and delivers instant, high-performance broadband over major networks, including AT&T, FirstNet ®, T-Mobile, and Verizon, enabling teams to establish secure connectivity anywhere in seconds. This press release features multimedia. View the full release here: The AirgainConnect® Go-Kit Pro shown here is a rugged, TSA-compliant case housing a compact, all-in-one 5G connectivity solution with a built-in battery that delivers up to 15 hours of runtime. It integrates a 5G modem, high-performance antennas, a Wi-Fi 6 router, GPS, and multi-carrier eSIM support—engineered for rapid deployment in mission-critical field operations. Go-Kit Pro combines a 5G modem, Wi-Fi 6 router, Gigabit Ethernet, GPS, and embedded high-performance antennas inside a TSA carry-on-compliant, ultra-rugged case. Engineered for teams that need connectivity beyond the vehicle—such as first responders, disaster recovery crews, mobile command units, and remote operators—it offers plug-and-play simplicity, multi-carrier eSIM support, and up to 15 hours of continuous battery life in a compact, deploy-anywhere form factor. 'Go-Kit Pro sets a new standard for portable broadband,' said Brian Makarowski, Vice President of Product Management and Marketing at Airgain. 'It's incredibly compact, rugged, and purpose-built to deliver reliable connectivity in the field—whether you're responding to an emergency, operating in a remote location, or extending coverage beyond the vehicle.' The Go-Kit Pro has already proven valuable for public safety teams in real-world deployments. 'We used the Go-Kit Pro during a large public event where coverage can be unpredictable, and it performed reliably the entire time. It's compact enough to deploy discreetly for unmarked surveillance work, and the ability to switch between dedicated public safety and commercial networks gave us the flexibility we needed in the field,' said Chris Hinson, Chatham-Savannah County (Georgia) - Counter Narcotics Team. Unlike consumer hotspot devices, and more cumbersome router-and-antenna kits, Go-Kit Pro delivers enterprise-grade multi-network performance in a portable form factor. It's ideal for fast-moving teams who need broadband connectivity without the complexity of vehicle installation or the coverage and security limitations of traditional mobile hotspots. With support for up to four eSIM profiles, automatic carrier failover, Wi-Fi 6 (up to 64 connected devices), and Gigabit Ethernet, Go-Kit Pro functions as a full-featured mobile network hub. The Go-Kit Pro also complements Airgain's AC-Fleet™ solution—providing seamless connectivity both inside and outside the vehicle. Organizations can now build a unified mobile communications strategy, starting with Go-Kit Pro for rapid tactical field deployments, and scale vehicle fleet-wide deployment with AC-Fleet. Availability AirgainConnect ® Go-Kit Pro is certified on all major carriers including AT&T, FirstNet, T-Mobile, and Verizon, and it is available today through Airgain sales channels and authorized resellers. To learn more, visit AirgainConnect ® Go-Kit Pro. About Airgain, Inc. Headquartered in San Diego, California, Airgain, Inc. (NASDAQ: AIRG) is a leading provider of advanced wireless connectivity solutions that drive cutting-edge innovation in 5G technology. We are committed to delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. Our mission is to connect the world through integrated, innovative, and optimized wireless solutions. Our diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. For more information, visit or follow us on LinkedIn and X. Airgain, AirgainConnect, and the Airgain logo are trademarks or registered trademarks of Airgain, Inc. All other trademarks are the property of their respective owners . FirstNet, FirstNet Trusted™ and the FirstNet logo are registered trademarks and service marks of the First Responder Network Authority. All other marks are the property of their respective owners. View source version on CONTACT: Media Contact: Cyrus Sy [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: TECHNOLOGY MOBILE/WIRELESS 5G LAW ENFORCEMENT/EMERGENCY SERVICES TELECOMMUNICATIONS PUBLIC POLICY/GOVERNMENT NETWORKS HARDWARE PUBLIC SAFETY SOURCE: Airgain, Inc. Copyright Business Wire 2025. PUB: 06/04/2025 08:53 AM/DISC: 06/04/2025 08:52 AM
Yahoo
30 minutes ago
- Yahoo
58th Festival of Flowers welcomes visitors with topiaries, new concert series
GREENWOOD, S.C. (WSPA) – More than 50 topiaries are highlighted in the 58th annual Festival of Flowers in the City of Greenwood, from May 31 to the end of June. Guests can expect more events this weekend, including a dozen musicians on Friday, June 6, and Saturday, June 7. There will also be nine food trucks, more than 30 crafters and classes offered during the Garden Symposium on Friday. Classes include tea making, succulent building, a community garden tour and a woods walk. Tickets are required for the symposium at The $25 admission includes lunch for the day. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
